首页> 外文期刊>Clinica chimica acta: International journal of clinical chemistry and applied molecular biology >Identification of differentially displayed proteins in cerebrospinal fluid of Parkinson's disease patients: a proteomic approach.
【24h】

Identification of differentially displayed proteins in cerebrospinal fluid of Parkinson's disease patients: a proteomic approach.

机译:帕金森氏病患者脑脊液中差异展示蛋白的鉴定:一种蛋白质组学方法。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Clinical proteomics has been widely used to identify differentially displayed proteins in blood and cerebrospinal fluid (CSF) to understand the molecular and cellular events leading to Parkinson's disease (PD). The close connection between CSF and the brain offers reliable and reproducible way to assess the majority of changes in the brain proteome profile directly into CSF throughout the course of neurodegeneration. METHODS: We identified the differentially displayed proteins in CSF of PD patients as compared with controls using two-dimensional polyacrylamide gel electrophoresis (2-D PAGE) and mass spectrometry. RESULTS: Comparative 2-D PAGE electrophoretograms of CSF of PD patients with case controls and/or neurological controls revealed significant differential display of six protein spots. The differentially displayed proteins were identified as serum albumin precursor, serum albumin chain-A, hemoglobin beta fragment, mutant globin, proline rich repeat 14 (PRR 14) and serum transferrin N-terminal lobe. Although the level of hemoglobin beta fragment and mutant globin was attenuated, serum albumin precursor, serum albumin chain-A, PRR 14 and serum transferrin N-terminal lobe were augmented in PD patients as compared with case controls. The level of serum albumin chain-A, PRR 14 and serum transferrin N-terminal lobe was not significantly altered when compared with neurological controls. CONCLUSIONS: The results obtained thus suggest that differential display of CSF serum albumin precursor, serum albumin chain-A, PRR 14 and serum transferrin N-terminal lobe could be associated with neuronal dysfunction and hemoglobin/globin with the onset/progression of PD in humans.
机译:背景:临床蛋白质组学已被广泛用于鉴定血液和脑脊液(CSF)中差异显示的蛋白质,以了解导致帕金森氏病(PD)的分子和细胞事件。 CSF与大脑之间的紧密联系提供了可靠且可重现的方法,可以评估在整个神经变性过程中直接进入CSF的大脑蛋白质组概况的大部分变化。方法:我们使用二维聚丙烯酰胺凝胶电泳(2-D PAGE)和质谱法,与对照组相比,确定了PD患者脑脊液中差异显示的蛋白质。结果:具有病例对照和/或神经系统对照的PD患者脑脊液的2-D PAGE电泳图谱显示了六个蛋白质斑点的显着差异显示。差异显示的蛋白质被鉴定为血清白蛋白前体,血清白蛋白链A,血红蛋白β片段,突变体球蛋白,富含脯氨酸的重复序列14(PRR 14)和血清转铁蛋白N末端叶。尽管PD患者的血红蛋白β片段和突变体球蛋白的水平降低,但与病例对照相比,PD患者的血清白蛋白前体,血清白蛋白链-A,PRR 14和血清转铁蛋白N-末端叶增高。与神经系统对照组相比,血清白蛋白链A,PRR 14和血清转铁蛋白N末端的水平没有明显改变。结论:由此得出的结果表明,脑脊液血清白蛋白前体,血清白蛋白链A,PRR 14和血清转铁蛋白N末端叶的差异显示可能与人类PD的发生/发展有关,与神经元功能障碍和血红蛋白/球蛋白有关。 。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号